Lacobris 200mg Tablet contains lacosamide, an antiepileptic agent indicated for the treatment of partial-onset seizures in patients with epilepsy. Lacosamide acts by selectively enhancing slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes, and inhibiting repetitive neuronal firing. This mechanism contributes to its efficacy in reducing seizure frequency. Lacobris is typically administered orally, with a recommended dosage individualized based on clinical response and tolerability. It may be used as monotherapy or adjunctive therapy in adults and pediatric patients aged four years and above. The pharmacokinetic profile of lacosamide demonstrates rapid absorption, high bioavailability, and minimal protein binding, with renal excretion as the primary elimination pathway. Common adverse effects include dizziness, headache, nausea, and fatigue, which are generally mild to moderate in intensity. Caution is advised in patients with cardiac conduction abnormalities due to potential PR interval prolongation. Lacobris should be prescribed following a thorough assessment of the patient’s medical history and concomitant medications to minimize drug interactions. Regular monitoring of clinical response and side effects is recommended to optimize therapeutic outcomes. This medication should be stored at room temperature, away from moisture and direct sunlight.